Durelli L - Search Results

1

Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.

Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Verdun E, Bradac GB, Riva A, Geuna M, Bergamini L, et al. Durelli L, et al. Mult Scler. 1995;1 Suppl 1:S32-7. Mult Scler. 1995. PMID: 9345396 Clinical Trial.

2

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, et al. Durelli L, et al. Neurology. 1994 Mar;44(3 Pt 1):406-13. doi: 10.1212/wnl.44.3_part_1.406. Neurology. 1994. PMID: 8145906 Clinical Trial.

3

Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment.

Durelli L, Bongioanni MR, Ferrero B, Ferri R, Imperiale D, Bradac GB, Bergui M, Geuna M, Bergamini L, Bergamasco B. Durelli L, et al. Neurology. 1996 Jul;47(1):123-9. doi: 10.1212/wnl.47.1.123. Neurology. 1996. PMID: 8710065 Clinical Trial.

4

Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.

Bongioanni MR, Durelli L, Ferrero B, Imperiale D, Oggero A, Verdun E, Aimo G, Pagni R, Geuna M, Bergamasco B. Bongioanni MR, et al. Among authors: durelli l. J Neurol Sci. 1996 Nov;143(1-2):91-9. doi: 10.1016/s0022-510x(96)00176-1. J Neurol Sci. 1996. PMID: 8981304 Clinical Trial.

5

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.

Durelli L, Bongioanni MR, Ferrero B, Imperiale D, Verdun E, Oggero A, Gentile E, Bradac GB, Bergui M, Bergamini L, Bergamasco B. Durelli L, et al. Mult Scler. 1996 Jul;1(6):366-71. doi: 10.1177/135245859600100617. Mult Scler. 1996. PMID: 9345419 Clinical Trial.

6

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L; INCOMIN Trial Study Group. Barbero P, et al. Among authors: durelli l. Mult Scler. 2006 Feb;12(1):72-6. doi: 10.1191/135248506ms1247oa. Mult Scler. 2006. PMID: 16459722 Clinical Trial.

7

Multiple sclerosis. I. The immune pathogenetic hypothesis.

Bergamini L, Durelli L. Bergamini L, et al. Among authors: durelli l. Riv Neurol. 1989 Sep-Oct;59(5):176-90. Riv Neurol. 1989. PMID: 2483961 Review.

8

Total body irradiation for myasthenia gravis: a long-term follow-up.

Durelli L, Ferrio MF, Urgesi A, Poccardi G, Ferrero B, Bergamini L. Durelli L, et al. Neurology. 1993 Nov;43(11):2215-21. doi: 10.1212/wnl.43.11.2215. Neurology. 1993. PMID: 8232932

9

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal.

Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Durelli L, et al. Neurology. 1998 Feb;50(2):570-1. doi: 10.1212/wnl.50.2.570. Neurology. 1998. PMID: 9484407 No abstract available.

10

Autoimmune events during interferon beta-1b treatment for multiple sclerosis.

Durelli L, Ferrero B, Oggero A, Verdun E, Bongioanni MR, Gentile E, Isoardo GL, Ricci A, Rota E, Bergamasco B, Durazzo M, Saracco G, Biava MA, Brossa PC, Giorda L, Pagni R, Aimo G. Durelli L, et al. J Neurol Sci. 1999 Jan 1;162(1):74-83. doi: 10.1016/s0022-510x(98)00299-8. J Neurol Sci. 1999. PMID: 10064173 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters